Prognostic Value of the CPS-EG Score in Locally Advanced Triple-Negative Breast Cancer: A Multicenter Retrospective Cohort Study
Preprint
- 1 January 2026
- preprint
- Published by Springer Nature in Research Square
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options and poor prognosis. Effective prognostic tools are essential to guide risk-adapted strategies following neoadjuvant chemotherapy (NACT). In this multicenter retrospective study, we evaluated 690 patients with locally advanced TNBC treated between 2010 and 2023 across 25 oncology centers. Patients were stratified into CPS-EG risk groups: low (0–1), intermediate (2–3), and high (≥4). The CPS-EG score was strongly associated with pathological complete response (pCR), recurrence, disease-free survival (DFS), and overall survival (OS). Five-year DFS rates were 80.6%, 53.2%, and 31.5% in the low-, intermediate-, and high-risk groups, respectively, while OS rates were 76.7%, 53.2%, and 48.8% (p<0.001). Multivariate analysis confirmed CPS-EG as an independent predictor of both DFS and OS after adjusting for clinicopathological factors. These findings highlight the CPS-EG score as a simple, cost-effective, and widely applicable prognostic tool that may improve post-NACT risk stratification and support treatment decisions, especially in resource-limited oncology settings.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerAnnals of Oncology, 2022
- Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapyEuropean Journal of Cancer, 2021
- Predictive markers for pathological complete response after neo-adjuvant chemotherapy in triple-negative breast cancerAnnals of Diagnostic Pathology, 2020
- Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS + EG scoreBreast Cancer Research and Treatment, 2019
- Validation of the CPS+EG and Neo-Bioscore staging systems after preoperative systemic therapy for breast cancer in a single center in ChinaThe Breast, 2018
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trialThe Lancet Oncology, 2018
- Molecular alterations in triple-negative breast cancer—the road to new treatment strategiesThe Lancet, 2017
- Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriersBreast Cancer Research and Treatment, 2016
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trialThe Lancet Oncology, 2014